Nuwellis

Nuwellis Current Liabilities

The Current Liabilities of Nuwellis (NUWE) as of Nov 9, 2026 is 3.03 M USD. In the previous year, Current Liabilities was 3.44 M USD — a change of -11.78% (lower).

Current Liabilities

3.03 MUSD

YoY

-11.78%

Last updated:

Current Liabilities of Nuwellis is 2025 3.03 M USD. Current Liabilities of Nuwellis was 2024 3.44 M USD. It decreases by -11.78% lower compared to the previous year.

The Nuwellis Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
4.34 M USD
Jan 1, 2019
5.13 M USD
Jan 1, 2020
6.01 M USD
Jan 1, 2021
5.17 M USD
Jan 1, 2022
7.08 M USD
Jan 1, 2023
3.91 M USD
Jan 1, 2024
3.44 M USD
Jan 1, 2025
3.03 M USD
The Nuwellis Current Liabilities history
YEARCurrent LiabilitiesYoY
3.03 MUSD-11.78%
3.44 MUSD-12.16%
3.91 MUSD-44.72%
7.08 MUSD+36.98%
5.17 MUSD-13.96%
6.01 MUSD+17.03%
5.13 MUSD+18.23%
4.34 MUSD+39.50%
3.11 MUSD-25.40%
4.17 MUSD-68.33%
13.17 MUSD+210.71%
4.24 MUSD-12.13%
4.82 MUSD+59.86%
3.02 MUSD-20.92%
3.81 MUSD+569.30%
570,000.00USD+26.67%
450,000.00USD+28.57%
350,000.00USD+45.83%
240,000.00USD+9.09%
220,000.00USD-40.54%
370,000.00USD+8.82%
340,000.00USD+13.33%
300,000.00USD+76.47%
170,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nuwellis Stock analysis

What does Nuwellis do? Nuwellis, Inc. develops, manufactures, and commercializes medical devices for ultrafiltration therapy, primarily the Aquadex SmartFlow and Aquadex FlexFlow systems. The Aquadex System includes a console with electromechanical pumps and an LCD screen, a disposable blood circuit set, and a catheter. It targets patients with fluid overload unresponsive to diuretics, indicated for adult and pediatric use from 20 kilograms. Hospitals and healthcare providers purchase these systems to manage fluid overload in patients who have failed diuretic therapy. The company focuses on selling the Aquadex System as a comprehensive solution for ultrafiltration therapy. Nuwellis markets the Aquadex SmartFlow system specifically for temporary or extended use in patients with fluid overload unresponsive to medical management. The Aquadex FlexFlow system is part of the same product line, designed for similar therapeutic applications. The company's revenue comes from the sale of the Aquadex System components, including the console, disposable blood circuit sets, and catheters. Healthcare facilities are the primary buyers, using these devices to treat patients requiring ultrafiltration therapy. The Aquadex System is positioned as a medical device solution for fluid overload cases where diuretics have failed. It consists of a console, disposable blood circuit set, and catheter, all sold together as a system. Hospitals and clinics purchase the Aquadex System to provide treatment options for patients who cannot be managed with standard diuretic therapy. The company's revenue model relies on the sale of the complete system and its disposable components to healthcare providers. Nuwellis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nuwellis stock

Current Liabilities of Nuwellis is 3.03 M USD in 2025.

Current Liabilities of Nuwellis changed from 3.44 M USD to 3.03 M USD, representing a -11.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Nuwellis since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Nuwellis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nuwellis

All Key Metrics — Nuwellis